Published in Biochem Cell Biol on May 06, 1993
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour Biol (2013) 0.80
The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: a meta-analysis including 7,107 subjects. Indian J Dermatol (2013) 0.75
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A (1997) 2.53
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J (1984) 2.45
Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol (1994) 2.12
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene (1992) 1.68
Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol (1994) 1.57
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis (2001) 1.53
Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol (1996) 1.52
The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region. J Biol Chem (1996) 1.51
Analysis of the anti-p53 antibody response in cancer patients. Cancer Res (1993) 1.49
Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica (1999) 1.46
Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J Immunol (1991) 1.46
Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine (2001) 1.37
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis (2005) 1.32
Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J Immunol (1992) 1.32
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology (1994) 1.27
General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol (2001) 1.25
Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol (2001) 1.21
c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol (1989) 1.19
Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol (1997) 1.17
Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis (1999) 1.15
The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. Nucleic Acids Res (1995) 1.15
Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol (1995) 1.08
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction. J Immunol (1993) 1.04
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol (1987) 0.97
P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer (2000) 0.94
Regulation of tumor necrosis factor gene expression and protein synthesis in murine macrophages treated with recombinant tumor necrosis factor. J Immunol (1990) 0.93
Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine (2001) 0.92
Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev (2001) 0.91
Analysis of antisense and double stranded RNA downregulation of A2 protein expression in Leishmania donovani. Mol Biochem Parasitol (2000) 0.89
A2rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene. Mol Biochem Parasitol (1998) 0.87
The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies. J Gen Virol (1986) 0.85
Inducible expression of suicide genes in Leishmania donovani amastigotes. J Biol Chem (1998) 0.83
Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother (2001) 0.83
Development of a p53 responsive GFP reporter; identification of live cells with p53 activity. J Biotechnol (2001) 0.81
Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. J Immunol (1991) 0.78
Leishmania donovani infection enhances macrophage viability in the absence of exogenous growth factor. J Leukoc Biol (1994) 0.78
Characterization of a beta-tubulin gene and a beta-tubulin gene products of Brugia pahangi. Mol Biochem Parasitol (1991) 0.78
Identification of a novel Brugia pahangi beta-tubulin gene (beta 2) and a 22-nucleotide spliced leader sequence on beta 1-tubulin mRNA. Mol Biochem Parasitol (1992) 0.77
Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele). Antimicrob Agents Chemother (2001) 0.75
The use of monoclonal antibodies for selection of a low-abundance mRNA: p53. Biochem Soc Trans (1984) 0.75